比较硝基咪唑类药物德拉马尼和普托马尼对耐多药和广泛耐药结核病的体外活性。
Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis.
机构信息
National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Institute, Capital Medical University, Beijing, China.
Department of Tuberculosis, Beijing Chest Hospital affiliated to Capital Medical University, BeijingTuberculosis and Thoracic Tumor Research Institute, Beijing, China.
出版信息
Eur J Clin Microbiol Infect Dis. 2019 Jul;38(7):1293-1296. doi: 10.1007/s10096-019-03551-w. Epub 2019 Apr 5.
Delamanid exhibited greater in vitro potency than pretomanid against multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB) isolates. The pretomanid minimum inhibitory concentration (MIC) values of four MDR-TB isolates were found to be resistant to delamanid ranging from 0.031 to 0.063 mg/L. A novel nonsynonymous mutation within the fbiA gene (Glu249Lys) may be contributing to high-level resistance to delamanid and pretomanid in Mycobacterium tuberculosis.
德拉马尼对耐多药（MDR）和广泛耐药（XDR）结核分枝杆菌（TB）分离株的体外活性大于普托马尼。发现四种耐多药 TB 分离株的普托马尼最低抑菌浓度（MIC）值对德拉马尼的耐药范围为 0.031 至 0.063 mg/L。结核分枝杆菌 fbiA 基因内的一种新的非同义突变（Glu249Lys）可能导致对德拉马尼和普托马尼的高水平耐药。
Zotero 插件